NextCure, Inc.
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer patients who do not respond to or have disease progression on current therapies. The company specializes in antibody-drug conjugates, or ADCs, which consist of monoclonal antibodies… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What NextCure, Inc. does
In the company’s own words
NextCure, Inc. (Nasdaq: NXTC) is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer patients who do not respond to or have disease progression on current therapies. The company specializes in antibody-drug conjugates, or ADCs, which consist of monoclonal antibodies conjugated to cytotoxic drugs via chemical linkers. NextCure's core competency lies in understanding biological pathways, biomarkers, and cellular interactions within the tumor microenvironment to design targeted cancer therapies.
The company's lead product candidate is SIM0505, a novel ADC directed to cadherin-6, or CDH6, featuring a proprietary topoisomerase 1 inhibitor payload. Developed by partner Simcere Zaiming Pharmaceutical Co., Ltd., SIM0505 targets multiple solid tumors including ovarian, endometrial, non-small cell lung, and renal cancers. NextCure obtained exclusive worldwide rights to develop, manufacture, and commercialize SIM0505 outside of China, Hong Kong, Macau, and Taiwan. The company dosed its first patient in a Phase 1 clinical trial in October 2025 and expects to provide dose escalation data in the second quarter of 2026.
The company's second major program is LNCB74, a B7-H4 targeted ADC being developed under a cost-sharing collaboration with LigaChem Biosciences, Inc. LNCB74 combines a NextCure-generated monoclonal antibody with LigaChem's proprietary linker technology and targets breast, ovarian, and endometrial cancers. The first patient was dosed in January 2025, with a trial update expected in the second half of 2026.
NextCure maintains a dedicated, state-of-the-art cGMP manufacturing facility with 2,000-liter production capacity, though internal manufacturing operations were paused in March 2024 as part of a strategic restructuring. The company also pursues partnerships for clinical programs NC410 and NC525, as well as preclinical non-oncology programs including NC181 for Alzheimer's disease and NC605 for osteogenesis imperfecta. More information is available at www.nextcure.com.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- BALTIMORE, MD
- Fiscal year end
- December
- CIK
- 1661059
- SIC
- 2834
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns NextCure, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · NextCure, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do NextCure, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of NextCure, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in NextCure, Inc.'s last four quarterly filings that the numbers alone won't show?”